Skip to main content
Erschienen in: Current Oncology Reports 1/2020

01.01.2020 | Palliative Medicine (A Jatoi, Section Editor)

Nausea and Vomiting: a Palliative Care Imperative

verfasst von: Rita J. Wickham

Erschienen in: Current Oncology Reports | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review was undertaken to survey recent literature for research reports and comprehensive clinical reviews addressing the pharmacologic management of nausea and vomiting (N&V) in advanced cancer. The goal was to integrate findings in a comprehensive article that incorporates palliative care concepts into antiemetic treatment.

Recent Findings

There are few published studies of N&V in advanced cancer; such research may be limited by the multicausal nature of N&V and participant burden to patients with life-limiting disease. Most articles are written by oncologists who also specialize in palliative care, and those addressing adverse effects of drugs used as antiemetics are found in other literature. Articles addressing more novel therapies, like cannabinoids and medical marijuana, are uncommon in the oncology literature.

Summary

N&V in patients with progressive or advanced cancer is often multicausal. Nausea is more common and persistent, and even mild nausea is bothersome and may cause anxiety or depression. The mechanisms of nausea and vomiting overlap, but different neural pathways constitute the final pathway for each—the brainstem for vomiting and higher brain regions for nausea. Common causes of N&V in advanced cancer include constipation, opioids, and malignant bowel obstruction. About 40% have undetermined causes and may be exacerbated by impaired gastric emptying, chemical imbalances, or other factors. Several drugs that have antiemetic effects and act at different receptors are used to palliate N&V. There is a paucity of research that supports palliative antiemetic choices, and other research is needed to define potential therapeutic strategies that capitalize on differences between nausea and vomiting.
Literatur
3.
Zurück zum Zitat • Napadow V, Sheehan JD, Kim J, et al. The brain circuitry underlying the temporal evolution of nausea in humans. Cereb Cortex. 2013;23:806–13. https://doi.org/10.1093/cercor/bhs073. Functional MRI study investigated brain regions involved in temporal evolution of nausea; greater nausea intensity was associated sustained activation in a broader network of interoceptive, limbic, somatosensory, and cognitive processing areas in the human brain. CrossRefPubMed • Napadow V, Sheehan JD, Kim J, et al. The brain circuitry underlying the temporal evolution of nausea in humans. Cereb Cortex. 2013;23:806–13. https://​doi.​org/​10.​1093/​cercor/​bhs073. Functional MRI study investigated brain regions involved in temporal evolution of nausea; greater nausea intensity was associated sustained activation in a broader network of interoceptive, limbic, somatosensory, and cognitive processing areas in the human brain. CrossRefPubMed
5.
Zurück zum Zitat •• Wickham RJ. Revisiting the physiology of nausea and vomiting—challenging the paradigm. Support Care Cancer. Online first: 06 August 2019. https://doi.org/10.1007/s00520. Current, in-depth review of differing physiological mechanisms, neural pathways, transmitters and receptors for vomiting and for nausea; new proposed paradigm for nausea and for vomiting. •• Wickham RJ. Revisiting the physiology of nausea and vomiting—challenging the paradigm. Support Care Cancer. Online first: 06 August 2019. https://​doi.​org/​10.​1007/​s00520. Current, in-depth review of differing physiological mechanisms, neural pathways, transmitters and receptors for vomiting and for nausea; new proposed paradigm for nausea and for vomiting.
26.
Zurück zum Zitat Tachere RO, Modirrousta M. Beyond anxiety and agitation: a clinical approach to akathisia. Aust Fam Physician. 2017;46(5):296–8.PubMed Tachere RO, Modirrousta M. Beyond anxiety and agitation: a clinical approach to akathisia. Aust Fam Physician. 2017;46(5):296–8.PubMed
49.
Zurück zum Zitat Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429–40.CrossRef Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429–40.CrossRef
58.
Zurück zum Zitat •• National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017. https://doi.org/10.17226/24625. A comprehensive, in-depth review of existing evidence and summary recommendations regarding health effects of cannabis and cannabis-derived products, as well as potential therapeutic uses. This work was implemented to help advance research and inform public health decisions. CrossRef •• National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017. https://​doi.​org/​10.​17226/​24625. A comprehensive, in-depth review of existing evidence and summary recommendations regarding health effects of cannabis and cannabis-derived products, as well as potential therapeutic uses. This work was implemented to help advance research and inform public health decisions. CrossRef
59.
Zurück zum Zitat • Schleider LB-L, Mechoulam R, Lederman V, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018;49:37–43. https://doi.org/10.1016/j.ejim.2018.01.023. Analysis of routinely collected data regarding the benefits and burdens of medical marijuana, prescribed to almost 3000 cancer patients with symptomatic disease who were followed over 2 years. This article also describes the processes of physician prescription and nurse selection (with patient) of particular cannabis strains, dose escalation, and patient and family teaching. CrossRef • Schleider LB-L, Mechoulam R, Lederman V, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018;49:37–43. https://​doi.​org/​10.​1016/​j.​ejim.​2018.​01.​023. Analysis of routinely collected data regarding the benefits and burdens of medical marijuana, prescribed to almost 3000 cancer patients with symptomatic disease who were followed over 2 years. This article also describes the processes of physician prescription and nurse selection (with patient) of particular cannabis strains, dose escalation, and patient and family teaching. CrossRef
Metadaten
Titel
Nausea and Vomiting: a Palliative Care Imperative
verfasst von
Rita J. Wickham
Publikationsdatum
01.01.2020
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 1/2020
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-020-0871-6

Weitere Artikel der Ausgabe 1/2020

Current Oncology Reports 1/2020 Zur Ausgabe

Gynecologic Cancers (NS Reed, Section Editor)

Low-grade Serous Tumors: Are We Making Progress?

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Genetic Testing in Prostate Cancer

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.